Stock AMPH AMPHASTAR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Real-time Estimate Cboe BZX
Other stock markets
 03:09:40 2024-05-15 pm EDT 		5-day change 1st Jan Change
42.53 USD +2.98% Intraday chart for Amphastar Pharmaceuticals, Inc. -1.04% -32.47%
May. 08 Transcript : Amphastar Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08 Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
AQ
Transcript : Amphastar Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024
Amphastar: Q1 Earnings Snapshot
AQ
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 EPS $1.04, vs. Street Est of $0.79
MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 Revenue $171.8M, vs. Street Est of $174.7M
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Transcript : Amphastar Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing
MT
JPMorgan Initiates Amphastar Pharmaceuticals With Overweight Rating, Price Target is $60
MT
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
AQ
Sector Update: Health Care Stocks Advance Premarket Thursday
MT
Amphastar Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise
MT
Transcript : Amphastar Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMPH Stock
  4. News Amphastar Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW